Genome destabilization-associated phenotypes arising as a consequence of therapeutic treatment are suppressed by Olaparib
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0281168 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Mafuka Suzuki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Genome Stability Maintenance, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca K.K. and Merck Sharp & Dohme Corp., Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Malignancy is often associated with therapeutic resistance and metastasis, usually arising after therapeutic treatment. These include radio- and chemo-therapies, which cause cancer cell death by inducing DNA double strand breaks (DSBs). However, it is still unclear how resistance to these DSBs is induced and whether it can be suppressed. Here, we show that DSBs induced by camptothecin (CPT) and radiation jeopardize genome stability in surviving cancer cells, ultimately leading to the development of resistance. Further, we show that cytosolic DNA, accumulating as a consequence of genomic destabilization, leads to increased cGAS/STING-pathway activation and, ultimately, increased cell migration, a precursor of metastasis. Interestingly, these genomic destabilization-associated phenotypes were suppressed by the PARP inhibitor Olaparib. Recognition of DSBs by Rad51 and genomic destabilization were largely reduced by Olaparib, while the DNA damage response and cancer cell death were effectively increased. Thus, Olaparib decreases the risk of therapeutic resistance and cell migration of cells that survive radio- and CPT-treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Genome Stability Maintenance, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo, Japan.
- Department of Biological Science and Technology, Tokyo University of Science, Niijuku, Katsushika-ku, Tokyo, Japan.
- Department of NCC Cancer Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Yushima, Bunkyou-ku, Tokyo, Japan.
ORCID-Profile: Mitsunori Shiroishi
Förderung
- AstraZeneca K.K. and Merck Sharp & Dohme Corp.
- Japan Society for the Promotion of Science
Zitieren
APA
Suzuki, M., Fujimori, H., Wakatsuki, K., Manaka, Y., Asai, H., Hyodo, M., Matsuno, Y., Kusumoto-Matsuo, R., Shiroishi, M., & Yoshioka, K. I. (2023). Genome destabilization-associated phenotypes arising as a consequence of therapeutic treatment are suppressed by Olaparib. PLOS ONE. https://doi.org/10.1371/journal.pone.0281168
Vancouver
Suzuki M, Fujimori H, Wakatsuki K, Manaka Y, Asai H, Hyodo M, et al. Genome destabilization-associated phenotypes arising as a consequence of therapeutic treatment are suppressed by Olaparib. PLOS ONE. 2023. doi:10.1371/journal.pone.0281168
BibTeX
@article{Suzuki2023,
author = {Suzuki, Mafuka and Fujimori, Haruka and Wakatsuki, Kakeru and Manaka, Yuya and Asai, Haruka and Hyodo, Mai and Matsuno, Yusuke and Kusumoto-Matsuo, Rika and Shiroishi, Mitsunori and Yoshioka, Ken-Ichi},
title = {Genome destabilization-associated phenotypes arising as a consequence of therapeutic treatment are suppressed by Olaparib},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0281168}
}
EUVIMED